|Other Names||Probable ATP-dependent RNA helicase DHX58, Probable ATP-dependent helicase LGP2, Protein D11Lgp2 homolog, RIG-I-like receptor 3, RLR-3, RIG-I-like receptor LGP2, RLR, DHX58, D11LGP2E, LGP2|
|Target/Specificity||The synthetic peptide sequence is selected from aa 56-69 of HUMAN DHX58|
|Format||Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Acts as a regulator of DDX58/RIG-I and IFIH1/MDA5 mediated antiviral signaling. Cannot initiate antiviral signaling as it lacks the CARD domain required for activating MAVS/IPS1-dependent signaling events. Can have both negative and positive regulatory functions related to DDX58/RIG-I and IFIH1/MDA5 signaling and this role in regulating signaling may be complex and could probably depend on characteristics of the infecting virus or target cells, or both. Its inhibitory action on DDX58/RIG-I signaling may involve the following mechanisms: competition with DDX58/RIG-I for binding to the viral RNA, binding to DDX58/RIG-I and inhibiting its dimerization and interaction with MAVS/IPS1, competing with IKBKE in its binding to MAVS/IPS1 thereby inhibiting activation of interferon regulatory factor 3 (IRF3). Its positive regulatory role may involve unwinding or stripping nucleoproteins of viral RNA thereby facilitating their recognition by DDX58/RIG-I and IFIH1/MDA5. Involved in the innate immune response to various RNA viruses and some DNA viruses such as poxviruses, and also to the bacterial pathogen Listeria monocytogenes. Can bind both ssRNA and dsRNA, with a higher affinity for dsRNA. Shows a preference to 5'- triphosphorylated RNA, although it can recognize RNA lacking a 5'- triphosphate.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Mosbruger, T.L., et al. J. Infect. Dis. 201(9):1371-1380(2010)
Parisien, J.P., et al. J. Virol. 83(14):7252-7260(2009)
Li, X., et al. J. Biol. Chem. 284(20):13881-13891(2009)
Murali, A., et al. J. Biol. Chem. 283(23):15825-15833(2008)
Saito, T., et al. Proc. Natl. Acad. Sci. U.S.A. 104(2):582-587(2007)
Komuro, A., et al. J. Virol. 80(24):12332-12342(2006)
Yoneyama, M., et al. J. Immunol. 175(5):2851-2858(2005)
Cui, Y., et al. Genomics 78(3):129-134(2001)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.